1. Commissioner of the FDA approves drug to reduce bone marrow suppression caused by chemotherapy. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy. Published February 12, 2021.
2. CDK4/6 inhibition enhances anti-tumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy;Lai;J. Immunother. Cancer,2020
3. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial [published online ahead of print, 2020 Dec 21;Daniel;Int. J. Cancer,2020
4. Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial;Weiss;Ann. Oncol.,2019
5. Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: results from a randomized, double-blind, placebo-controlled phase II study;Hart;Adv. Ther.,2021